Pneumococcal Vaccine Over 65

Introduction; PCV13 Impact on IPD and serotype distribution for the remaining disease burden ; Incidence of non-Invasive Pneumococcal Pneumonia before and after PCV13 recommendation for adults ≥65yo; U.S. trends in pneumonia hospitalizations; Economic analysis of PCV13 for adults ≥65 year old ; Preliminary EtR and GRADE. Summary and timeline

Comments on this video are allowed in accordance with our comment policy:

This video can also be viewed at